The NAD+ Landscape, Demystified
What this cellular coenzyme actually does, why IV infusions may not be the answer, and what the evidence says about oral precursors
title: "The NAD+ Landscape, Demystified" dek: "What this cellular coenzyme actually does, why IV infusions may not be the answer, and what the evidence says about oral precursors" slug: "nad-and-longevity" date: "2026-04-14" tags: ["peptides", "education"]
NAD+ has become one of the most discussed molecules in longevity medicine, and with good reason. It sits at the intersection of cellular energy production, DNA repair, and aging biology in ways that are scientifically substantive — not marketing fiction. At the same time, the supplement and clinic industry has moved far ahead of the evidence, and claims about what NAD+ therapy can do for you often bear little resemblance to what the research actually supports.
This article covers the biology honestly, examines the main delivery approaches with their known limitations, and gives you a realistic picture of what is and isn't established.
What NAD+ Does in the Body
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme — a small molecule that assists enzymes in carrying out their functions. It participates in more than 500 biochemical reactions, with a central role in four areas:
Energy metabolism. NAD+ is the primary electron carrier in cellular respiration. When cells break down glucose or fat for energy, NAD+ shuttles electrons through the mitochondrial electron transport chain to generate ATP. Without adequate NAD+, this process is impaired.
DNA repair. A family of enzymes called PARPs (poly-ADP ribose polymerases) depend on NAD+ as a substrate. PARPs detect and repair DNA strand breaks — a constant cellular housekeeping task. When DNA damage increases with age, PARP activity consumes more NAD+, contributing to its depletion.
Sirtuin activation. Sirtuins are a family of protein deacetylases that regulate gene expression, stress response, and metabolic efficiency. SIRT1, for example, activates PGC-1α, which drives mitochondrial biogenesis — the production of new mitochondria. Sirtuins require NAD+ as a cofactor; they are essentially inactive without adequate levels.
Circadian regulation. NAD+ levels oscillate across the sleep-wake cycle and are connected to circadian clock function. SIRT1 helps regulate the CLOCK/BMAL1 complex that governs circadian rhythm. Declining NAD+ is thought to be one reason circadian disruption becomes more common with age.
The core problem: NAD+ levels decline with age, starting noticeably after age 30 and becoming more pronounced by the 50s and beyond. This decline is described in The Tao of NAD (Dr. Jin-Xiong She, PhD — founder of Jinfiniti Precision Medicine, molecular biologist with 400+ peer-reviewed publications) as being associated with a wide spectrum of age-related dysfunction, including fatigue, metabolic disruption, and cognitive decline. The biological basis for NAD+'s importance is not in dispute; what remains more contested is how effectively external interventions can correct it.
Why Delivery Method Matters More Than People Realize
The problems begin when you try to actually raise cellular NAD+ levels. The molecule is large and charged — it does not easily cross cell membranes. This has major practical implications for every delivery approach.
Intravenous NAD+
IV NAD+ infusions have become a popular clinic offering, often priced at hundreds to thousands of dollars per session. The intuition is straightforward: inject NAD+ directly into the bloodstream and the cells get what they need.
The biology is less cooperative. Dr. She conducted observations on IV NAD+ therapy through his clinical practice and testing work. His findings were striking: approximately 70 percent of subjects showed a three- to ten-fold increase in hs-CRP — a sensitive marker of systemic inflammation — following IV infusions. His interpretation is that the body treats a sudden influx of NAD+ as a foreign substance, mounting an inflammatory response before the liver clears it.
His conclusion, stated plainly: "I cannot recommend IV infusion" for anti-aging or performance goals. He notes that the NAD+ molecule is too large to efficiently pass through cell membranes, meaning IV-delivered NAD+ may not meaningfully raise intracellular levels — which is where it needs to be to drive its biological effects. Any benefits are described as "temporary" at best.
IV NAD+ may have a role in specific acute contexts — there is emerging interest in neurological applications and addiction recovery. But as a routine longevity intervention, the evidence base is not persuasive, and the inflammatory signal is a legitimate concern.
Subcutaneous NAD+
Subcutaneous injection of NAD+ can modestly elevate circulating levels, but according to Dr. She's observations, it "rarely achieves optimum levels" as measured by intracellular testing. He frames it as a secondary option for those who prefer injectables while also using oral precursors.
Oral NAD+ Supplements
The same membrane problem affects oral NAD+ tablets: the intact molecule is too large to efficiently cross the gut barrier. Most oral NAD+ products have limited utility for raising intracellular levels. This is why the field has largely shifted toward precursors — compounds that the body converts into NAD+ inside the cell, sidestepping the membrane problem by entering via their own transporters.
The Precursor Landscape
Four main NAD+ precursors are in active use and study.
Nicotinamide (NAM)
Nicotinamide (niacinamide) is a simple form of vitamin B3. It can raise NAD+ levels in some individuals, but Dr. She's clinical testing found it unreliable — a substantial share of users showed no measurable improvement in intracellular NAD+ after supplementation. He excluded it from his formulations for this reason. It remains inexpensive and widely available, but the response variability is a real limitation.
Niacin (Nicotinic Acid)
Niacin is the most clinically documented form of vitamin B3. At high doses — 500 to 2,000 mg daily — it can raise NAD+ levels and has demonstrated cardiovascular benefits in certain contexts. One peer-reviewed study published in Cell Metabolism (Volume 32, Issue 1, July 2020) found high-dose niacin improved muscle strength and symptoms in adult-onset mitochondrial myopathy — a meaningful, specifically cited finding.
The downsides are also well-documented: niacin causes vasodilatory flushing at therapeutic doses, and higher-dose chronic use is associated with liver toxicity, gout, and adverse cardiovascular events in some populations. Very high intracellular NAD+ levels (above approximately 150 μM by intracellular testing) appear potentially harmful. Dr. She describes a case in which intractable insomnia in a long-term high-dose niacin user resolved when NAD+ levels were brought down from an extreme elevation to an optimal range. Monitoring intracellular NAD+ levels is described as essential for anyone using high-dose niacin.
NR (Nicotinamide Riboside)
NR is a form of vitamin B3 that converts to NAD+ through a two-step enzymatic process inside the cell. It has shown promise in preclinical studies and human trials for raising circulating NAD+ biomarkers, and does not carry the flushing or liver concerns associated with high-dose niacin.
A 2022 systematic review of NAD+ precursors and cognitive health (Campbell JM, Nutrients, 14(15):3231) found the preclinical evidence base substantial and encouraging. Across multiple disease models, the strongest signals emerged in Alzheimer's disease and other dementias; human clinical evidence was rated as promising but still thin. The same review concluded NR was well-tolerated with no safety signals in toxicology studies — a meaningful baseline given the limited long-term human trial data available.
The key limitation: most human trials of NR have been relatively small and short. The preclinical evidence is robust; the human clinical evidence is promising but still maturing.
NMN (Nicotinamide Mononucleotide)
NMN requires only a single enzymatic step to convert to NAD+, making it chemically the closest of the precursors. Whether this proximity translates to superior efficacy in practice is still being worked out.
Notable clinical findings: A randomized controlled trial published in the Journal of Diabetes Investigation (November 2020) found that NMN supplementation produced meaningful gains in skeletal muscle insulin sensitivity — improvements the authors described as roughly equivalent to what would be expected from a 10 percent reduction in body weight. Separately, a Japanese randomized, double-blind, placebo-controlled trial (2022) found 12-week NMN supplementation improved sleep quality and reduced daytime drowsiness in older adults. These are legitimate trials, though sample sizes were modest and replication is needed.
Side effects reported with NMN include headaches and drowsiness in some users.
Combining NR and NMN
Some formulations combine both NR and NMN on the premise that they use complementary pathways in NAD+ biosynthesis. This is a plausible mechanistic rationale. Head-to-head trials comparing combination formulas to single-precursor approaches are limited.
What the Evidence Honestly Supports
The biological importance of NAD+ in aging is substantiated. The hallmarks-of-aging framework — which includes mitochondrial dysfunction, impaired DNA repair, cellular senescence, and chronic inflammation — maps directly onto mechanisms dependent on NAD+. This is not marketing language; it reflects serious longevity research from major institutions.
The honest summary: NAD+ precursors, particularly NR and NMN, can reliably raise circulating NAD+ biomarkers and show promising signals in specific areas — metabolic health, sleep quality, cognitive preservation. Large, long-duration randomized trials in humans demonstrating hard clinical outcomes — reduced disease burden, mortality benefit — are still in progress or pending.
IV NAD+ as a longevity approach has a questionable evidence base and a documented risk of inflammatory response in a meaningful proportion of users. Oral precursors are safer, more cost-effective, and better supported for routine use.
Practical Considerations for People Over 50
If you are considering NAD+ support:
- Oral precursors (NR or NMN) are the best-supported starting point for routine wellness use
- Dosing ranges seen in clinical practice: NMN is commonly used at 250–500 mg daily; NR at similar ranges, though optimal doses remain under investigation
- Intracellular NAD+ testing (distinct from blood serum testing) is an emerging monitoring approach that may provide more meaningful data about cellular levels
- People on medications that affect insulin sensitivity — steroids, certain antipsychotics, HIV medications — should discuss any NAD+ supplementation with their prescribing physician
- The cancer interaction is genuinely unsettled: some research suggests NAD+ may support immune surveillance against tumors; other findings raise concern that highly elevated NAD+ could fuel cancer cell metabolism. Until this is better resolved, caution is warranted for anyone with active cancer
Safety & Disclaimer
This article is educational. It is not medical advice and should not be used to guide supplementation decisions without involving a qualified physician.
NAD+ biology is a legitimate and active area of scientific research. However, clinical translation is still evolving, and many claims circulating in the wellness industry significantly outpace what published human trials currently support. Supplement quality varies widely; dosing accuracy and manufacturing standards are not uniformly regulated.
If you are over 50, taking prescription medications, or managing any chronic condition — especially metabolic disease, cardiovascular disease, or any history of cancer — please discuss NAD+ precursor use with your physician before starting. Baseline lab monitoring and follow-up testing is prudent if you choose to pursue this approach. The goal is to work with your biology, not around it.